Cullinan Therapeutics, Inc. balance sheet

At the end of fiscal 2022, Cullinan Therapeutics, Inc. had total assets of $561m, total liabilities of $26.1m and shareholders' equity of $535m. It held $156m in cash against $0 of debt: net cash of $156m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cullinan Therapeutics, Inc.: balance sheet, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022
Cash and equivalents	168	60	156
Total current assets	212	297	474
Total assets	215	437	561
Accounts payable	10	3	3
Total current liabilities	14	12	22
Total debt	0	0	0
Total liabilities	14	12	26
Shareholders' equity	199	425	535
Net debt (negative = net cash)	−168	−60	−156
Shares outstanding	—	44m	46m

US$ millions unless shown otherwise. Fiscal quarters.

Cullinan Therapeutics, Inc.: balance sheet, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Total current assets	447	344	329	297	322	623	582	474
Total assets	480	464	453	437	437	667	617	561
Accounts payable	4	2	2	3	6	3	2	3
Total current liabilities	10	6	8	12	17	62	27	22
Total liabilities	10	6	8	12	18	63	31	26
Shareholders' equity	467	456	443	425	419	605	586	535
Shares outstanding	44m	44m	44m	44m	45m	45m	46m	46m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cullinan Therapeutics, Inc.